Kura Oncology Inc. (NASDAQ:KURA) shares saw unusually-strong trading volume on Monday . Approximately 131,646 shares traded hands during trading, an increase of 12% from the previous session’s volume of 117,656 shares.The stock last traded at $3.25 and had previously closed at $2.89.

Several equities research analysts recently commented on KURA shares. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday, March 22nd. Citigroup Inc. cut their target price on shares of Kura Oncology from $19.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 21st. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a research report on Tuesday, June 21st.

The stock’s market capitalization is $57.72 million. The stock has a 50-day moving average of $2.89 and a 200-day moving average of $3.96.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Equities research analysts forecast that Kura Oncology Inc. will post ($1.70) earnings per share for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.